TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Three Times a Day BIAsp-70 Compared to Two Times a Day BIAsp-30 in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with type 2 diabetes~* Current treatment using intermediate-acting, long-acting insulin (including long-acting insulin analogue) or pre-mixed human insulin for at least 24 weeks~* HbA1c at least 7.5% and below 10.0%~Exclusion Criteria:~* Proliferative retinopathy or maculopathy requiring acute treatment~* Impaired hepatic and/or renal function~* Cardiac diseases~* Uncontrolled hypertension~* Known hypoglycemia unawareness or recurrent major hypoglycemia

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Bosentan on Endothelial Function in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diabetes mellitus type 2 of \>2 years duration~2. Albuminuria~Exclusion Criteria:~1. Age \>80 years~2. Myocardial infarction/unstable angina within three months prior to randomisation~3. Decompensated congestive heart failure or functional class 3 and 4.~4. Changes in dosage of any vasodilator drugs during the preceding six weeks~5. Women of fertile age.~6. Impaired hepatic function (2 times upper normal limit of aminotransferases ASAT and ALAT)~7. Ongoing treatment with glibenclamide, cyclosporin or warfarin~8. Any concomitant disease or condition that may interfere with the possibility for the patient to comply with or complete the study protocol~9. Participant in an ongoing study~10. Unwillingness to participate following oral and written information

- Gender: ALL
- Minimum Age: None
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Bosentan (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Immune Response Approximately 5 to 6 Years After Receiving Different Formulations of GSK Bio Hep B Vaccine

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects should have participated in the primary study and should have received the first primary dose of vaccination more than five years ago and less than six years ago before blood sampling in this long-term follow-up study.~* Written informed consent obtained from the subject for the long-term follow-up.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Recipient of a primary or re-transplanted deceased donor kidney or a primary or re-transplanted non-human leukocyte antigen (HLA) living donor kidney (ie., HLA identical or 0 antigen mismatch deceased donor kidneys are allowed).~Exclusion Criteria:~* Patient has previously received an organ transplant other than a kidney~* Patient receiving chronic steroid therapy at time of transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alemtuzumab High-Risk Patients (Type: EXPERIMENTAL): Alemtuzumab, tacrolimus, mycophenolate mofetil and steroids; High risk patients: Panel reactive antibody ≥ 20% or re-transplant or African American
- Conventional High-Risk Patients (Type: ACTIVE_COMPARATOR): Rabbit anti-thymocyte globulin, tacrolimus, mycophenolate mofetil and steroids; High risk patients: Panel reactive antibody ≥ 20% or re-transplant or African American
- Alemtuzumab Low- Risk Patients (Type: EXPERIMENTAL): Alemtuzumab, tacrolimus, mycophenolate mofetil and steroids; Low risk patients: Panel reactive antibody \< 20% and first transplant and non-African American
- Conventional Low-Risk Patients (Type: ACTIVE_COMPARATOR): Basiliximab, tacrolimus, mycophenolate mofetil and steroids; Low risk patients: Panel reactive antibody \< 20% and first transplant and non-African American

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Droxidopa in Treating Patients With Neurogenic Hypotension

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
PROTOCOL ENTRY CRITERIA:~--Disease Characteristics--~* Orthostatic hypotension due to autonomic nervous system failure Fall in systolic blood pressure (supine to standing) of at least 20 mm Hg and diastolic blood pressure of at least 15 mm Hg AND Symptoms of hypotension such as dizziness, light-headedness, unsteadiness, dimming or blurred vision~* History of syncope or near-syncope~--Prior/Concurrent Therapy--~* Endocrine therapy: No concurrent adrenergics Concurrent fludrocortisone allowed~* Other: Concurrent indomethacin, support garments, and high salt diets allowed

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Microbiologically confirmed clinical diagnosis of interdigital tinea pedis~* If female and of child bearing potential, prepare to abstain from sexual intercourse or use a reliable method of contraception during the study (e.g., condom, intra-uterine device (IUD), oral, transdermal, injected or implanted hormonal contraceptives).~* A confirmed clinical diagnosis of interdigital tinea pedis. Lesions are to be predominately interdigital but may extend to other areas of the foot (the non-interdigital lesions must not be hyperkeratotic).~* The presence of tinea pedis infection, confirmed by the observation of segmented fungal hyphae during a microscopic potassium hydroxide (KOH) wet mount examination (potassium hydroxide mount preparation).~* Identification of an appropriate dermatophyte by culture sent to the central laboratory. The appropriate dermatophytes are Trichophyton rubrum, Trichophyton mentagrophyte or Epidermophyton floccosum.~Exclusion Criteria:~* Use of any of the following within the indicated timeline:~* Oral or injectable steroids~* Any oral anti-fungals within 4 weeks of the study start~* Use of topical corticosteroids or any other topical antipruritics on the feet within 72 hours of the study start.~* Any prescription or over-the-counter (OTC) topical antifungals on the feet within two weeks prior to study entry~* Use of any antihistamines within 72 hours of the study start.~* Any known hypersensitivity to butenafine or other antifungal agents.~* Evidence of any concurrent dermatophytic infection of toe nails (onychomycosis) or other dermatological condition of the foot that may interfere with the Investigator's evaluation of tinea pedis.~* Patients with recurrent tinea pedis (more than 3 infections in the past 12 months) who have been unresponsive to previous antifungal therapy.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Butenafine cream 1% (Taro) (Type: EXPERIMENTAL): Butenafine cream manufactured by Taro applied for 7 days
- Lotrimin Ultra (butenafine) 1% (Type: ACTIVE_COMPARATOR): Lotrimin Ultra (butenafine) applied for 7 days
- Vehicle (Type: PLACEBO_COMPARATOR): Butenafine vehicle applied for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigating the Role of the Polyol Pathway in the Central Nervous System Production of Fructose

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 15 Type 2 DM subjects with HbA1C \> 7.5%~* 15 Type 1 DM subjects with HbA1C \> 7.5%~* Age 18-60~* BMI ≥18 kg/m2~* Weight ≤ 285 pounds~Exclusion Criteria:~* Creatinine \> 1.5 mg/dL, Hgb \< 10 mg/dL, ALT \> 2.5 X ULN,~* untreated thyroid disease,~* uncontrolled hypertension,~* known neurological disorders,~* untreated psychiatric disorders,~* malignancy,~* bleeding disorders,~* current or recent steroid use in last 3 months,~* illicit drug use;~* for women: pregnancy, actively seeking pregnancy, or breastfeeding; inability to enter~* MRI/MRS

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- type 2 diabetes mellitus (Type: ACTIVE_COMPARATOR): Subjects with type 2 diabetes on insulin.
- type 1 diabetes mellitus (Type: ACTIVE_COMPARATOR): Subjects with type 1 diabetes on insulin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: B-type Natriuretic Peptide and Glucose Metabolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~written informed consent no disease history BNP level within the normal range Normal renal function (serum creatinine of more than 1.3 mg/dL and/or creatinin clearance greater than 80ml/min) Normal ECG~Exclusion Criteria:~systolic blood pressure \< 90 mmHg subjects on any medication abnormal glucose metabolism history of anaphylaxis

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- B-type natriuretic peptide (Type: ACTIVE_COMPARATOR): the effect of B-type natriuretic peptide on glucose metabolism will be compared with placebo during an intravenous glocose tolerance test
- Placebo (Type: PLACEBO_COMPARATOR): comparison of the effect of b-type natriuretic peptide on glucose metabolism and placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study 302: BLI4900 Versus an FDA-approved Comparator in Adult Subjects Prior to Colonoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication.~* 18 to 85 years of age (inclusive)~* If female, and of child-bearing potential, is using an acceptable form of birth control.~* Negative serum pregnancy test at screening, if applicable~* In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study~Exclusion Criteria:~* Subjects with known or suspected ileus, gastrointestinal obstruction, gastroparesis, gastric retention, bowel perforation, toxic colitis or megacolon.~* Subjects with inflammatory bowel disease who have a history of any bowel resection (small intestine or colon), suspected active inflammation, or symptoms suggestive of obstruction or known bowel stricture.~* Subjects who had previous significant gastrointestinal surgeries.~* Subjects who have regularly used laxatives or colon motility altering drugs in the last month (i.e. more than 2-3 times per week) and/or laxative use within 72 hours prior to administration of the preparation~* Subjects with uncontrolled pre-existing electrolyte abnormalities, or those with clinically significant electrolyte abnormalities based on Visit 1 laboratory results.~* Subjects taking diuretics, anti-hypertensive medications, including angiotensin converting enzyme (ACE) inhibitors and Angiotensin II receptor blockers (ARBs), or chronic NSAIDs, that have not been stable for 30 days.~* Subjects with uncontrolled hypertension.~* Subjects taking antibiotics within 7 days of colonoscopy.~* Subjects with severe renal, hepatic or cardiac insufficiency.~* Subjects with an abnormal and clinically significant physical examination or ECG finding at Visit 1.~* Subjects undergoing insulin therapy for any indication.~* Subjects with impaired consciousness that predisposes them to pulmonary aspiration.~* Subjects undergoing colonoscopy for foreign body removal and/or decompression.~* Subjects taking tricyclic antidepressants.~* Subjects using drugs of abuse, including abused prescription medications.~* Subjects who are withdrawing from alcohol or benzodiazepines.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- BLI4900 (Type: EXPERIMENTAL): Experimental bowel preparation solution for oral ingestion
- FDA Approved Control (Type: ACTIVE_COMPARATOR): FDA approved bowel preparation solution for oral ingestion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post-operative Dental Pain Study Comparing Analgesic Efficacy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects aged 18-45 years with moderate-to-severe dental pain assessed by verbal rating scale (VRS) and confirmed by a score of at least 50 mm out of 100 mm using a visual analogue scale (VAS) following surgical removal of third molars, of which at least one has to be a mandibular partially bony or full bony impaction.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Paracetamol 1000 mg (Type: EXPERIMENTAL): Paracetamol 1000 mg
- Paracetamol 500 mg (Type: EXPERIMENTAL): Paracetamol 500 mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Replacement of Vitamin D in Patients With Active Tuberculosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (≥16 years on 1st March 2009) Males and Nonpregnant females~* Active Pulmonary Tuberculosis diagnosed by Sputum Smear positivity for Acid fast bacilli (AFB)~* Diagnosis within one week of inclusion into study~* Not already on antituberculous treatment~* Not receiving vitamin D replacement or supplementation~Exclusion Criteria:~* History of having been treated with antimycobacterial therapy for \< 6 months or with \< 4 first-line anti-tuberculous drugs~* Extra- pulmonary TB~* Immune suppressed; with HIV infection, hepatic, renal failure, malignancy, diabetes mellitus~* Sarcoidosis, hyperparathyroidism~* Already on or requiring corticosteroids, immunosuppressive agents, thiazide diuretics~* Breast feeding or pregnant~* Symptomatic cardiac disease~* Seriously ill or moribund patients with advanced respiratory impairment (cor pulmonale, hypercapnia, respiratory acidosis, congestive cardiac failure)~* Allergy/sensitivity to study drugs or their formulations.~* Concomitant use of drugs known to interfere with vitamin D levels; phenytoin, phenobarbital, carbamazepine, theophylline~* Inability or unwillingness of subject or legal guardian/representative to give written informed consent.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cholecalciferol (Vitamin D) (Type: EXPERIMENTAL): Intramuscular injection of VITAMIN D, 600,000 UNITS WILL BE GIVEN TO THE TEST SUBJECTS AT WEEK 0 and at week 4 OF the TRIAL
- SALINE, INTRAMUSCULAR INJECTION (Type: PLACEBO_COMPARATOR): NORMAL SALINE INJECTION WILL BE GIVEN TO THE CONTROL SUBJECTS at week 0 and week 4 of the trial

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~1. Previously completed 24 weeks of therapy and 4 weeks of follow-up in the REPLACE study~2. With regard to female patients: women who are postmenopausal or willing to use two medically acceptable methods of contraception for the duration of the study with pregnancy testing conducted at every scheduled office visit~3. Total serum calcium ≤ ULN based on local laboratory results prior to randomization~4. Serum 25(OH) vitamin D ≤ 1.5 times the ULN within approximately 8 weeks prior to randomization~Main Exclusion Criteria:~1. Any disease or condition that, in the opinion of the investigator, has a high probability of precluding the patient from completing the study or being able to appropriately comply with study requirements~2. Use of raloxifene hydrochloride or intravenous (IV) bisphosphonates since the end of participation in the REPLACE trial~3. Chronic (ie, ≥ 1 month exposure) use of systemic corticosteroids, oral bisphosphonates, calcitonin, fluoride tablets, or cinacalcet hydrochloride~4. Pregnant or lactating women~5. Any condition that would, in the investigator's opinion in consultation with the sponsor, preclude the safe use of PTH~6. Use of any experimental drug other than NPSP558 within 3 months of baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 25 µg dose (Type: EXPERIMENTAL): 25 µg
- 50 µg dose (Type: EXPERIMENTAL): 50 µg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Emotion Regulation Interventions for Alcohol-Related Sexual Aggression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Single~* Male~* Age 21-30~* Heterosexually active within past year~* Heavy episodic drinker~* Self-reported history of sexual aggression~Exclusion Criteria:~* History of alcohol problems~* Medical condition or medications that contraindicate alcohol consumption

- Gender: MALE
- Minimum Age: 21 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Cognitive Restructuring & Alcohol Condition (Type: EXPERIMENTAL): Participants will receive a brief online training regarding the use of cognitive restructuring skills to cope with negative emotions. They will then consume an alcoholic beverage in the lab.
- Mindfulness & Alcohol Condition (Type: EXPERIMENTAL): Participants will receive a brief online training regarding the use of mindfulness skills to cope with negative emotions. They will then consume an alcoholic beverage in the lab.
- Nutrition Information & Alcohol Condition (Type: EXPERIMENTAL): Participants will receive general information about nutrition. They will then consume an alcoholic beverage in the lab.
- Cognitive Restructuring & No Alcohol Condition (Type: EXPERIMENTAL): Participants will receive a brief online training regarding the use of cognitive restructuring skills to cope with negative emotions. They will then consume a non-alcoholic beverage in the lab.
- Mindfulness & No Alcohol Condition (Type: EXPERIMENTAL): Participants will receive a brief online training regarding the use of mindfulness skills to cope with negative emotions. They will then consume a non-alcoholic beverage in the lab.
- Nutrition Information & No Alcohol Condition (Type: NO_INTERVENTION): Participants will receive general information about nutrition. They will then consume a non-alcoholic beverage in the lab.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete